To determine whether chronic oxytocin administration improves neural and behavioral outcomes in ASD.

Autism is an early-onset neurodevelopmental disorder characterized by repetitive and constrictive patterns of behaviors, interests, or activities, as well as difficulties with social interaction and communication. Oxytocin has been proposed as a potential treatment for autism spectrum disorder (ASD) due to its role in social bonding and emotional regulation

We performed a comprehensive search on PubMed, Google Scholar, Cochrane Library, and ClinicalTrials.gov from inception to September 2025, searching for RCTs that evaluated the neural, behavioral, and biological outcomes of Chronic oxytocin(more than 4 weeks administration of oxytocin) in patients with autism compared to placebo. The analysis is registered with PROSPERO (CRD420251166227) and followed the PRISMA guidelines. Two independent reviewers screened and extracted data from eligible studies. Outcomes were pooled using Rev-Man (random-effects model) and reported as mean differences (MD) with 95% confidence intervals. Heterogeneity was assessed using I² statistics. The risk of bias was evaluated using Cochrane RoB 2.0.